2024
Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis
Squires P, Puckett J, Ryland K, Kamal-Bahl S, Raut M, Doshi J, Huntington S. Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis. Clinical Lymphoma Myeloma & Leukemia 2024, 24: e350-e358.e1. PMID: 39034204, DOI: 10.1016/j.clml.2024.05.023.Peer-Reviewed Original ResearchR/R MCLOverall survivalTreatment patternsRelapsed/refractory mantle cell lymphomaReal-world treatment patternsBruton tyrosine kinase inhibitorCovalent Bruton tyrosine kinase inhibitorMantle cell lymphomaTyrosine kinase inhibitorsDevelopment of novel therapeuticsMCL patientsCell lymphomaThird-lineRetrospective studyTreatment initiationResponse durationAdverse eventsElderly patientsKinase inhibitorsPatient subpopulationsPatientsAll-causeNovel therapeuticsEconomic burdenSurvival
2023
Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma
Garg M, Puckett J, Kamal-Bahl S, Raut M, Ryland K, Doshi J, Huntington S. Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma. Future Oncology 2023, 20: 317-328. PMID: 38050764, DOI: 10.2217/fon-2023-0191.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaReal-world treatment patternsLarge B-cell lymphomaB-cell lymphomaTreatment patternsMedicare beneficiariesFirst-line treatmentFront-line treatmentHealthcare resource useHealth resource useElderly Medicare beneficiariesUnmet need existsOverall survivalR-CHOPMedicare patientsLater linesOlder adultsTreatmentPatientsLymphomaNeed existsSurvivalTwo-thirdsResource useSame periodReal-World Treatment Patterns, Overall Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients with Mantle Cell Lymphoma (MCL) after Failure of Covalent Btki Treatment
Squires P, Puckett J, Ryland K, Kamal-Bahl S, Raut M, Doshi J, Huntington S. Real-World Treatment Patterns, Overall Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients with Mantle Cell Lymphoma (MCL) after Failure of Covalent Btki Treatment. Blood 2023, 142: 2326. DOI: 10.1182/blood-2023-181024.Peer-Reviewed Original ResearchR mantle cell lymphomaHealthcare resource useLines of therapyMantle cell lymphomaMedian overall survivalOverall survivalTreatment initiationElderly patientsTyrosine kinase inhibitorsTreatment patternsPrior linesStandard chemotherapyU.S. patientsCell lymphomaReal-world treatment patternsRefractory mantle cell lymphomaBruton tyrosine kinase inhibitorsCause total costsFourth-line treatmentService Medicare coverageThird-line settingProgression-free survivalHalf of patientsHealthcare resource utilizationLarge unmet needReal-World Treatment Patterns and Overall Survival Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Claims Data
Huntington S, Chang H, Fu A, Loefgren C, Lu X. Real-World Treatment Patterns and Overall Survival Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Claims Data. Blood 2023, 142: 2428. DOI: 10.1182/blood-2023-178755.Peer-Reviewed Original ResearchHematopoietic stem cell transplantAcute myeloid leukemiaNon-transplant recipientsR AML patientsIndex dateAML patientsOverall survivalTreatment patternsND patientsIntensive chemotherapyAML diagnosisR patientsDiagnosis codesTransplant recipientsOlder patientsSupportive careIntensive therapyContinuous enrollmentNovel therapiesLarge US administrative claims databaseUnmet needRefractory acute myeloid leukemia patientsReal-world treatment patternsUS administrative claims databaseAcute myeloid leukemia patients
2022
Real-World Treatment Patterns and Transfusion Burden Among Newly Diagnosed Older Adults with Acute Myeloid Leukemia
Zeidan A, Cheng W, Kamalakar R, Miller C, Bui C, Montez M, Yee T, Wu Z, Huntington S. Real-World Treatment Patterns and Transfusion Burden Among Newly Diagnosed Older Adults with Acute Myeloid Leukemia. Blood 2022, 140: 3282-3283. DOI: 10.1182/blood-2022-160002.Peer-Reviewed Original ResearchReal-world treatment patternsAcute myeloid leukemiaTransfusion burdenTreatment patternsMyeloid leukemiaOlder adultsLeukemiaReal-World Treatment Patterns and Outcomes after Ibrutinib Discontinuation Among Elderly Medicare Beneficiaries with Chronic Lymphocytic Leukemia: An Observational Study
Huntington S, De Nigris E, Puckett J, Kamal-Bahl S, Farooqui M, Ryland K, Sarpong E, Yang X, Doshi J. Real-World Treatment Patterns and Outcomes after Ibrutinib Discontinuation Among Elderly Medicare Beneficiaries with Chronic Lymphocytic Leukemia: An Observational Study. Blood 2022, 140: 7939-7940. DOI: 10.1182/blood-2022-155903.Peer-Reviewed Original ResearchTreatment Patterns of Follicular Lymphoma in the United States: A Claims Analysis
Huntington S, Appukkuttan S, Wang W, Du Y, Hopson S, Babajanyan S. Treatment Patterns of Follicular Lymphoma in the United States: A Claims Analysis. Journal Of Health Economics And Outcomes Research 2022, 115-122. DOI: 10.36469/jheor.2022.38070.Peer-Reviewed Original ResearchLines of therapyFirst-line treatmentFollicular lymphomaTreatment patternsRituximab monotherapyCommon first-line treatmentReal-world treatment patternsFourth-line therapyOptimal treatment sequencingThird-line therapyDuration of therapyInitiation of treatmentCommon indolent lymphomaLine of treatmentNumber of patientsActive regimensRituximab therapyBaseline characteristicsMost patientsRetrospective cohortIBM MarketScanPrimary outcomeContemporary cohortIndolent lymphomaMedian timeTreatment Patterns of Follicular Lymphoma in the United States: A Claims Analysis
Huntington S, Appukkuttan S, Wang W, Du Y, Hopson S, Babajanyan S. Treatment Patterns of Follicular Lymphoma in the United States: A Claims Analysis. Journal Of Health Economics And Outcomes Research 2022, 9: 115-122. PMID: 36348725, PMCID: PMC9603402, DOI: 10.36469/001c.38070.Peer-Reviewed Original ResearchLines of therapyFirst-line treatmentFollicular lymphomaTreatment patternsRituximab monotherapyCommon first-line treatmentReal-world treatment patternsFourth-line therapyOptimal treatment sequencingThird-line therapyDuration of therapyInitiation of treatmentCommon indolent lymphomaLine of treatmentNumber of patientsActive regimensRituximab therapyBaseline characteristicsMost patientsRetrospective cohortIBM MarketScanPrimary outcomeContemporary cohortIndolent lymphomaMedian time
2016
Characterization of Real World Treatment Patterns and Outcomes Among Older Adults with Chronic Lymphocytic Leukemia in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare Database
Mato A, Jahnke J, Li P, Mehra M, Ladage V, Mahler M, Huntington S, Doshi J. Characterization of Real World Treatment Patterns and Outcomes Among Older Adults with Chronic Lymphocytic Leukemia in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare Database. Blood 2016, 128: 4773. DOI: 10.1182/blood.v128.22.4773.4773.Peer-Reviewed Original ResearchChronic lymphocytic leukemiaOlder CLL patientsOverall survivalTreatment initiationCox regressionCLL patientsClinical trialsFirst treatmentNovel agentsChlorambucil monotherapyOlder adultsLymphocytic leukemiaMedicare feeClinical practiceLow-income subsidy statusReal-world treatment patternsRecent landmark clinical trialsCLL/SLL patientsLogistic regressionOlder individualsAdvisory CommitteeGilead SciencesReal-world outcome dataAnemia/thrombocytopeniaApproval of ibrutinib